Filtered By:
Source: Thrombosis Research
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 219 results found since Jan 2013.
Increased rates of hand ischemia following arterial cannulation in patients with severe COVID19-related pneumonia
Thrombotic complications in patients with COVID19 infection are increasingly reported due to the hypercoagulable state induced by the disease [1 –3]. In particular, arterial thromboembolism has been described in up to 4% of patients, with ischemic stroke being the most common thrombotic event [2]. While catheter-related upper extremity venous thromboses are anecdotally reported [4,5], at the moment no reports are available regarding upper extremity arterial thrombosis following cannulation.
Source: Thrombosis Research - June 14, 2020 Category: Hematology Authors: Walter Dorigo, Aaron Fargion, Laura Paperetti, Roberto Falso, Manuela Bonizzoli, Paolo Fontanari, Loredana Poggesi, Carlo Pratesi Tags: Letter to the Editors-in-Chief Source Type: research
In silico features of ADAMTS13 contributing to plasmatic ADAMTS13 levels in neonates with congenital heart disease
Risk factors contributing to heightened thrombosis in pediatric congenital heart disease (CHD) patients are not fully understood. Among the neonatal CHD population, those presenting with single ventricular physiology are at the highest risk for perioperative thrombosis. The von Willebrand factor and ADAMTS13 interactions have emerged as causative risk factors for pediatric stroke and could contribute to heightened thrombosis in CHD neonates.
Source: Thrombosis Research - May 30, 2020 Category: Hematology Authors: Upendra K. Katneni, David D. Holcomb, Nancy E. Hernandez, Nobuko Hamasaki-Katagiri, Ryan C. Hunt, Haim Bar, Juan C. Ibla, Chava Kimchi-Sarfaty Tags: Full Length Article Source Type: research
Combined prognostic significance of D-dimer level and platelet count in acute ischemic stroke
D-dimer level and platelet count (PC) have been reported separately as significant independent predictors of Acute Ischemic Stroke (AIS). Here, we aimed to investigate the combined prognostic value of abnormal D-dimer level and PC as defined for specific in-hospital and long-term outcomes in AIS patients.
Source: Thrombosis Research - May 15, 2020 Category: Hematology Authors: Yue Liu, Fang Li, Hongwei Sun, Yanyan Sun, Hongwei Sun, Yun Zhai, Fan Yang, Jiamin Wang, Anqi Feng, Jingbo Zhao, Ying Tang Tags: Full Length Article Source Type: research
A single-center comparative study of the SWIM technique in the treatment of acute ischemic stroke due to anterior circulation occlusion
Stent retriever (SR) thrombectomy has been established as the standard of care for acute ischemic stroke due to large vessel occlusion. However, more effective endovascular treatments are still desired because better revascularization correlates with improved clinical results [1]. The combined use of stent retrieval and direct contact aspiration has been attempted to improve recanalization [2]. The SWIM technique (Solitaire stent retriever in combination with the intracranial support catheter aspiration for mechanical thrombectomy), as a novel treatment method based on the concept of the combination of stent retrieval and ...
Source: Thrombosis Research - May 14, 2020 Category: Hematology Authors: Liuwei Chen, Rui Shen, Xiang Zhang, Zuoquan Chen, Hao Lu, Xiaoyu Zhou, Jiping Sun, Quanbin Zhang Tags: Letter to the Editors-in-chief Source Type: research
Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation
Efficacy and safety of vitamin K antagonists (VKAs) is optimised in atrial fibrillation (AF) patients when the International Normalised Ratio (INR) is 2.0 –3.0. Anticoagulation control comparing different ethnic groups is limited, although epidemiological studies suggest poorer INR control in non-white cohorts.
Source: Thrombosis Research - May 5, 2020 Category: Hematology Authors: Hanis Zulkifly, Paola Cheli, Ivana Lutchman, Ying Bai, Gregory Y.H. Lip, Deirdre A. Lane Tags: Full Length Article Source Type: research
Increased prevalence of VTE reported by Klok and colleagues, the numbers don't add up
In this study the authors report that 31% of patients met the composite outcome of having a thrombotic complication which they define as having a pulmonary embolism, deep vein thrombosis, or an ischemic stroke. The study included 184 patients with 31 patients having a thrombotic complication. This adds up to an incidence of 16.8%, not 31%.
Source: Thrombosis Research - April 25, 2020 Category: Hematology Authors: Yonatan Y. Greenstein Tags: Letter to the Editors-in-Chief Source Type: research
Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119)
After solid organ or hematopoietic stem cell transplantation (HSCT), the risk of arterial or venous thromboembolism (VTE) is high (1 –7). Oral anticoagulation represents the mainstay for stroke prevention in atrial fibrillation (SPAF) and VTE treatment. The pharmacodynamic and pharmacokinetic profiles of vitamin k antagonists (VKA) represent a challenge especially in the setting of transplantation, also due to the high risk of bleeding (8) and due to complex co-medications of transplant recipients.
Source: Thrombosis Research - April 23, 2020 Category: Hematology Authors: Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Luise Tittl, Katja Sockel, Jan Moritz Middecke, Martin Bornh äuser Tags: Letter to the Editors-in-Chief Source Type: research
Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY
Edoxaban is licensed in many countries around the world, following successful phase-III trials in stroke prevention in atrial fibrillation (SPAF) and treatment of venous thromboembolism (VTE), but at present, little is known about edoxaban-related bleeding complications in daily care. Using data from a prospective, non-interventional oral anticoagulation registry, we analysed rates, management and outcome of edoxaban-related bleeding. Between 1 October 2011 and 28 February 2019, 996 patients were enrolled in the edoxaban cohort and a total of 891 bleeding events were observed (53.2% ISTH minor, 41.9% clinically relevant no...
Source: Thrombosis Research - April 18, 2020 Category: Hematology Authors: Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Luise Tittl, Ulrike H änsel, Ines Beyer-Westendorf, Heike Mizera, Thomas Schreier, Elke Festerling, Antje Reitter, Marianne Spindler, Martin Bornhäuser Tags: Full Length Article Source Type: research
Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials
Heart failure (HF) is associated with an increased incidence of thromboembolic events. Antithrombotic treatment could reduce the stroke risk, whereas increase the bleeding risk. Whether antithrombotic treatment should be a routine therapy for HF and sinus rhythm (SR) patients remains unanswered.
Source: Thrombosis Research - April 17, 2020 Category: Hematology Authors: Chi Zhang, Na Wang, Nan-Nan Shen, Ling-Cong Kong, Jie He, Yue Wu, Da Feng, Zhi-Chun Gu Tags: Review Article Source Type: research
Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation
Ischemic heart disease and stroke are major causes of death and morbidity worldwide. Coronary and cerebrovascular events are a consequence of thrombus formation caused by atherosclerotic plaque rupture or embolism, both of which result from platelet activation and aggregation and thrombin-mediated fibrin generation via the coagulation cascade [1]. In addition, thrombin is also one of the most effective platelet activators [2]. We focused on a novel thrombus formation mechanism called thrombin-mediated platelet stimulation and established thrombin-induced platelet aggregation [3].
Source: Thrombosis Research - February 20, 2020 Category: Hematology Authors: Keisuke Tsuda, Tatsunori Natori, Mie Shimizu, Yoko Ishigaku, Kiyotaka Oi, Shinsuke Narumi, Asami Kamada, Makiko Yoshida, Kazumasa Oura, Tetsuya Maeda, Yasuo Terayama Tags: Letter to the Editors-in-Chief Source Type: research
Management of major bleeding outcomes under antithrombotic therapy in real-life
Bleeding is the most serious undesirable event of antithrombotic therapy, though this treatment has shown benefits in terms of venous or arterial thrombosis prevention, particularly in case of atrial fibrillation, stroke, venous thromboembolism, and coronary disease.
Source: Thrombosis Research - January 9, 2020 Category: Hematology Authors: F. Moustafa, A. Corriger, C. Lambert, A. Barres, C. Camminada, D. Teissandier, J. Saint-Denis, F. Dutheil, J. Schmidt Tags: Letter to the Editors-in-Chief Source Type: research
Evaluation of long-term rt-PA effects on bEnd.3 endothelial cells under ischemic conditions; changes in ZO-1 expression and glycosylation of the bradykinin B2 receptor
Recombinant tissue plasminogen activator (rt-PA) has proven effective in the treatment of acute ischemic stroke, despite the increased risk of hemorrhagic transformation (HT), its major associated complication. Although it is known that HT is related to blood brain barrier (BBB) disruption, the underlying mechanisms are not well established. We assessed time-dependent effects of rt-PA on the bEnd.3 murine brain endothelial cell line subjected either to normoxia or to 2.5 h of oxygen and glucose deprivation (OGD), evaluating a longer period than has previously been done, beyond 6 h post-reoxygenation.
Source: Thrombosis Research - January 5, 2020 Category: Hematology Authors: Carme Gubern, Pau Comajoan, Gemma Huguet, Juan Manuel S ánchez, Joaquín Serena, Elisabet Kádár, Mar Castellanos Tags: Full Length Article Source Type: research
Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand
Novel oral anticoagulants (NOACs) and warfarin care bundles (e.g. genotyping, patient self-testing or self-management) are alternatives to usual warfarin care for stroke prevention in patients with atrial fibrillation (AF). We aim to evaluate the cost-effectiveness of NOACs and warfarin care bundles in patients with AF in a middle-income country, Thailand.
Source: Thrombosis Research - November 14, 2019 Category: Hematology Authors: Siok Shen Ng, Surakit Nathisuwan, Arintaya Phrommintikul, Nathorn Chaiyakunapruk Tags: Full Length Article Source Type: research
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation
Direct oral anticoagulants (DOACs) have been proven non-inferior or superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major hemorrhage, in patients with non-valvular atrial fibrillation (NVAF). We sought to investigate whether effectiveness and safety differs among apixaban, rivaroxaban and dabigatran.
Source: Thrombosis Research - November 12, 2019 Category: Hematology Authors: M. Jansson, S. Sj älander, V. Sjögren, H. Renlund, B. Norrving, A. Själander Tags: Full Length Article Source Type: research
P13. Abstract Title: Deep Mutational Scan of VWF to Define Mutations that Enhance or Impair Secretion
Von Willebrand Factor (VWF) is a multimeric glycoprotein that recruits platelets to sites of blood vessel injury and serves as a molecular chaperone for coagulation factor VIII (fVIII). Plasma VWF levels are a known risk factor for various thrombotic disorders including VTE, myocardial infarction, and stroke. GWAS studies have identified genetic variants in VWF that contribute to increased and decreased circulating VWF antigen levels. However, it is currently not known why some variants result in high VWF levels while others cause low VWF levels in circulation.
Source: Thrombosis Research - September 30, 2019 Category: Hematology Authors: T. Sparring, C. Kretz, K. Singh, H. Madarati Source Type: research
